- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Sonus expands relationship with Abbott
Ultrasound contrast developer Sonus Pharmaceuticals of Bothell,WA, has extended its relationship with Abbott Laboratories toinclude the clinical development and marketing of Sonus' EchoGenagent in the U.S.Last week's deal builds on a relationship between
Ultrasound contrast developer Sonus Pharmaceuticals of Bothell,WA, has extended its relationship with Abbott Laboratories toinclude the clinical development and marketing of Sonus' EchoGenagent in the U.S.
Last week's deal builds on a relationship between Sonus and Abbottthat began in 1993 for manufacturing of EchoGen. Under the newagreement, Abbott will pay Sonus $31 million in up-front, clinicalsupport, and milestone payments in return for U.S. marketing rights.In addition, Abbott paid $4 million for warrants to acquire 500,000shares of Sonus stock, equal to about 6% of shares outstanding.Sonus will receive 47% of net EchoGen revenues in the U.S. andthe company retains some co-promotion rights to EchoGen in theU.S.
EchoGen has completed phase III radiology and cardiology trialsin the U.S. and Sonus expects to file a new drug application forthe agent this year, followed by a filing with the European MedicinesEvaluation Agency. French contrast firm Guerbet has rights toEchoGen in Europe, while Daiichi Pharmaceutical retains marketingrights for the product in the Pacific Rim.
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.
